Total submissions: 7
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Invitae | RCV000553098 | SCV000649779 | pathogenic | Autosomal recessive limb-girdle muscular dystrophy type 2D | 2024-01-12 | criteria provided, single submitter | clinical testing | This sequence change replaces valine, which is neutral and non-polar, with phenylalanine, which is neutral and non-polar, at codon 242 of the SGCA protein (p.Val242Phe). The frequency data for this variant in the population databases is considered unreliable, as metrics indicate poor data quality at this position in the gnomAD database. This missense change has been observed in individuals with autosomal recessive limb-girdle muscular dystrophy, type 2D and autosomal recessive limb-girdle muscular dystrophy, type 2C (PMID: 10842281, 12566530). It has also been observed to segregate with disease in related individuals. ClinVar contains an entry for this variant (Variation ID: 471337). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt SGCA protein function with a positive predictive value of 95%. This variant disrupts the p.Val242 amino acid residue in SGCA. Other variant(s) that disrupt this residue have been observed in individuals with SGCA-related conditions (PMID: 7663524), which suggests that this may be a clinically significant amino acid residue. For these reasons, this variant has been classified as Pathogenic. |
Mendelics | RCV000553098 | SCV001140684 | pathogenic | Autosomal recessive limb-girdle muscular dystrophy type 2D | 2019-05-28 | criteria provided, single submitter | clinical testing | |
Fulgent Genetics, |
RCV000553098 | SCV002809363 | likely pathogenic | Autosomal recessive limb-girdle muscular dystrophy type 2D | 2021-07-01 | criteria provided, single submitter | clinical testing | |
Genome- |
RCV000553098 | SCV003931693 | likely pathogenic | Autosomal recessive limb-girdle muscular dystrophy type 2D | 2023-02-08 | criteria provided, single submitter | clinical testing | |
Baylor Genetics | RCV000553098 | SCV004203160 | pathogenic | Autosomal recessive limb-girdle muscular dystrophy type 2D | 2023-09-04 | criteria provided, single submitter | clinical testing | |
Revvity Omics, |
RCV000553098 | SCV004238639 | likely pathogenic | Autosomal recessive limb-girdle muscular dystrophy type 2D | 2023-02-05 | criteria provided, single submitter | clinical testing | |
Natera, |
RCV000553098 | SCV002087575 | pathogenic | Autosomal recessive limb-girdle muscular dystrophy type 2D | 2020-12-22 | no assertion criteria provided | clinical testing |